Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF CASH FLOWS

v3.19.3
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
12 Months Ended
Aug. 31, 2019
Aug. 31, 2018
Cash flows used in operating activities    
Net loss and comprehensive loss $ (4,158,413) $ (6,609,187)
Adjustments to reconcile net loss to net cash Used in operating activities:    
Stock based compensation 626,692 2,602,239
Depreciation and amortization 60,550 2,307
Inventory write-off (Note 8) 7,182 12,966
Bad Debt Expense 75,000  
Unrealized loss on marketable securities 16,434  
Unrealized foreign exchange   602
Common shares issued for services 234,500 781,056
Warrants issued for services 52,817 1,063,270
Change in working capital    
Accounts receivable (138,644) (245,458)
Inventory (47,345) (33,025)
Prepaid expenses and deposits 124,805 (44,041)
Accounts payable and accrued liabilities 100,626 3,210
Due to related parties 40,241 (34,835)
Deferred revenue   (17,083)
Net cash used in operating activities (3,005,555) (2,517,979)
Cash flows used in investing activities    
Investment in Poviva   (70,000)
Patent (122,982) (85,399)
Property & Equipment (646,183)  
Net cash used in investing activities (769,165) (155,399)
Cash flows from financing activities    
Investment from NCI 1,000,000  
Proceeds from issuance of equity 2,332,683 1,867,224
Net cash from financing activities 3,332,683 1,867,224
Decrease in cash and cash equivalents (442,037) (806,153)
Cash and cash equivalents, beginning of year 1,727,184 2,533,337
Cash and cash equivalents, end of year 1,285,147 1,727,184
Supplemental information of cash flows:    
Income taxes paid in cash 13,919  
Common shares issued to settle AP   12,000
Reclassification of NCI to additional paid in capital on acquisition $ 833,333 $ 318,820